Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Snap...actually the fundamentals look better on ENTU than INDX....I'll put that on watch also....
ctb, right....I shorted at 14 cents......
in your dreams.... Sure wish I could have!!!! LOL!!!
rickguy6, half these guys look at a max MSFT chart and think it started out as a penny stock!!! The other half are talking about $250 million market cap and are dumping their momo shares to the first half!!! LOL!!!
Hey Otis...did the buyers at 14 cents listen to you??? Good job!!!!
cashwealth, again you don't have a clue...show the board what a great investor you are and discuss dilution, market cap, etc.
Waitedg...I've been watching IDNX as an alternative to IDCO since IDCO was first mentioned here. IDNX seems on a steady trend up and they have frequent PR's on new biz. I'm not in yet, have been hoping to free up some funds soon. They have no debt, and their quarterly reports are improving quite a bit. A buy at $5 IMO.
http://finance.yahoo.com/q/ks?s=IDNX
derivativedallas, so you think AMEP will be about a $250 million market cap company??? I think you must mean 40-50 cents after a reverse split!!! Silly figures abound!!! Do you even know what dilution is or OS???? LOL!!!!
Don't be so cheap!!!! Pay the 2 bucks!!!! LOLOLOL!!!
This company's biggest asset is MW's mouth..I hope the company has it insured for about a billion dollars!!! LOL!!!
I don't think the European institutional investors were much impressed....the pps has gone down since that presentation.
He needs to walk the walk instead of talk the talk...IMO.
Sales yet?????
novicetrader, I have a small position in DOR, got in after their DOW announcement. Don't really understand that biz and plan to sell on any news spike. Also watch INSM moves, but haven't "played" that one at all yet...it seems to be a buy when it approaches a buck...
DOR BioPharma Maintains AMEX Listing
($0.27....slips by again...)
Friday December 9, 8:30 am ET
MIAMI--(BUSINESS WIRE)--Dec. 9, 2005--DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX: DOR - News) announced today that the Company received notice from the American Stock Exchange ("AMEX") that after a hearing on December 2 with a Listing Qualifications Panel of the Amex Committee on Securities ("the Panel"), it has been granted an extension within which to regain compliance with the continued listing standards of the AMEX.
Based on the presentation of DOR management at that meeting, the Panel unanimously agreed to grant DOR until March 31, 2006, to regain compliance with the continued listing standard of Section 1003 (a)(iii) of the AMEX Company Guide. This standard requires that member companies that have incurred losses in their five most recent fiscal years must maintain a shareholder equity balance of at least $6,000,000. If the Company has not achieved the minimum shareholder equity requirement by March 31, 2006, the Panel unanimously agreed that the AMEX should immediately move to delist the Company's common stock at that time with no further opportunity for the Company to appeal.
"We are very pleased with and appreciative of the continued support of the AMEX," stated Evan Myrianthopoulos, Chief Financial Officer of DOR. "We presented a comprehensive plan that we have been working on for several months and we continue to diligently move forward with the execution of that plan. We look forward to an eventful year in 2006 which we hope will include the FDA approval of orBec® for iGVHD."
About DOR BioPharma, Inc.
DOR BioPharma, Inc. is a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biomedical countermeasures. Our lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of intestinal Graft-versus-Host disease (iGVHD), a common serious complication of bone marrow transplantation for cancer, as well as other GI disorders characterized by severe inflammation. We plan to file a new drug application (NDA) with the FDA for orBec® for the treatment of iGVHD in early 2006.
In November we announced that we entered into a binding letter of intent to acquire Gastrotech Pharma A/S, a Danish biotech company developing therapeutics based on peptide hormones to treat cancer and gastrointestinal diseases and conditions.
Through our BioDefense Division, we are developing biomedical countermeasures pursuant to the paradigm established by the recently enacted Project BioShield Act of 2004. Our biodefense products in development are bioengineered vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin, both of which are considered serious bioterrorism threats. Our ricin toxin vaccine, RiVax(TM), has completed the clinical portion of its Phase I clinical trial in normal volunteers. We have also announced the initiation of a new botulinum toxin therapeutic development program based on rational drug design.
For further information regarding DOR BioPharma, please visit the Company's website located at http://www.dorbiopharma.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma's current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of orBec® for the treatment of iGVHD and the prospects for regulatory filings for orBec®. Where possible, DOR BioPharma has tried to identify these forward-looking statements by using words such as "anticipates", "believes", "intends", or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR BioPharma cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, that it will be able to maintain its listing on the American Stock Exchange ("AMEX") by completing a transaction which will provide it with shareholders' equity of at least $6 million, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for iGVHD include the risks that: because orBec® did not achieve statistical significance in its primary endpoint in the pivotal Phase III clinical study (i.e. a p-value of less than or equal to 0.05), the FDA may not consider orBec® approvable based upon existing studies, orBec® may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR BioPharma expects or may never gain approval; DOR BioPharma is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; or orBec® may not gain market acceptance; and others may develop technologies or products superior to orBec®. DOR BioPharma's business strategy has been revised to include the issuance of its securities to acquire companies or assets. DOR BioPharma presently is involved in negotiations which could result in the issuance of a significant number of shares of its equity securities, thereby diluting the equity interests of present stockholders. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR BioPharma's most recent reports on Form 10-QSB and Form 10-KSB. DOR BioPharma assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.
Contact:
DOR BioPharma Inc., Miami
Evan Myrianthopoulos, 305-534-3383
www.dorbiopharma.com
I guess the question is...did they just screw up, or was it deliberate and they got called on it??? Sets the timing back, IMO, if it was just a screw-up...
Maybe that's why UNB insiders were selling up to Dec. 7.....
http://www.canadianinsider.com/servlet/coReport/AllTransactionsServlet?ticker=UNB
And you thought you had problems...Botched Stock Trade Costs Japan Firm $225M
Friday December 9, 5:49 am ET
By Hans Greimel, Associated Press Writer
Botched Stock Trade Costs Brokerage Firm $225 Million, Sends Jitters Through Japanese Market
TOKYO (AP) -- Japan's government rebuked the Tokyo Stock Exchange and one of the country's biggest brokerage firms Friday after a typing error caused Mizuho Securities Co. to lose at least 27 billion yen, or $225 million, on a stock trade.
The glitch roiled the Japanese market, and jitters over the reliability of the exchange's trading system contributing to a 1.95 percent drop in the benchmark Nikkei 225 index Thursday.
The Nikkei rebounded 1.45 percent Friday to finish at 15,404.05, but the mishap triggered concern among some traders just a month after an embarrassing glitch at the Tokyo exchange shut down the market for almost an entire day.
The trouble began Thursday morning, when Mizuho Securities tried to sell 610,000 shares at 1 yen (less than a penny) apiece in a job recruiting firm called J-Com Co., which was having its public debut on the exchange.
It had actually intended to sell 1 share at 610,000 yen ($5,041).
Worse still, the number of shares in Mizuho's order was 41 times that J-Com's true outstanding amount, but the Tokyo Stock Exchange processed the order anyway.
Mizuho says it tried to cancel the order three times, but the exchange said it doesn't cancel transactions even if they are executed on erroneous orders.
By the end of the day, Mizuho Securities -- a division of the nation's second-largest bank, Mizuho Financial Group, Inc. -- had lost at least 27 billion yen. That total could escalate, however, as more trades settle, Mizuho Securities spokesman Hideki Sakuma said Friday, adding that the mishap was sparked by human error.
Japan's Financial Services Agency, the country's financial watchdog, began an immediate probe into what went wrong and how to prevent a repeat.
"In order to maintain the credibility of the Tokyo Stock Exchange, I very strongly want this issue to be resolved quickly," Economy and Banking Minister Kaoru Yosano told reporters Friday. "The first thing for the Financial Services Agency to do is to determine what happened in detail. Based on that, we will decide what is needed based on the rules and regulations."
Chief Cabinet Secretary Shinzo Abe echoed the sentiment saying that the Finance Ministry was working with Mizuho and the Tokyo Stock Exchange to formulate countermeasures for the future.
"It's extremely regrettable this caused confusion in the market and such huge problems for the related parties," Abe said.
J-Com's shares debuted at 672,000 yen ($5,600) on the Tokyo exchange's Mothers market and plunged to 572,000 yen ($4,767). But a big buy bid placed after Mizuho Securities' sell order helped lift J-Com to 772,000 yen ($6,433) at the close.
According to a Ministry of Finance filing, Morgan Stanley ended the session with a 31.2 percent stake in J-Com.
The Tokyo Stock Exchange suspended trading of J-Com on Friday, but declined to specify how it will sort out a mess created by the botched order.
Many of the sell orders have yet to be carried out, meaning further trading could "cause instability in the market," the exchange's managing director, Tomio Amano, said at a news conference.
The botched trade comes at a sensitive time for the Tokyo exchange, which has surged on record volume, spurred by buying from foreign investors.
For Mizuho Securities, the news is even worse.
Mizuho Financial Group said it would fully back its security arm's losses from erroneous trades on J-Com. But the red ink could wipe out Mizuho Securities' profit of 28 billion yen ($233 million) for the fiscal year that ended in March 2005.
XWG and VSNT...both very low OS... XWG buying back shares, VSNT earnings after close, first positive quarter since buyout of Poet....
http://finance.yahoo.com/q/cq?s=vsnt+xwg&d=v1
tech_vstr...I don't recall saying I would leave this board, can you show me that post??? If you can't, are you man enough to apologize??? I will honor that post if you find it....
Maybe all the Bagholders should go to Texas and pull the rig out of the mud!!!
More shares sold to buy pipe....money-losing OTC companies can't get bank loans so shareholders pay for everything!!! LOL!!!
Holy Cow Doubloon!!! And I was hoping for a toaster!!!!
bobsnook66....Don't worry about what inning this is (top or bottom of the ninth)...game about over, fat lady warming up.. BUT...it's a double header!!! New game starts after the RS or increase in Authorized!!!! Fresh Newbies in the lineup!!! LOL!!
Santa Claus rally....(GOOG and REDF start PPS's corrected)
Starshine at $11.98
Jagman at $10.90
Jagman at $6.93
SSKILL71 at $0.66
Beigledog @ $6.35
Beigledog @ $1.51
Doubloon @ $5.05
Doubloon @ $0.24
nlightn @ $422.86
nlightn @ $17.70
Sumisu @ $2.51
Sumisu @ $76.03
Waitedg @ $1.12
Waitedg @ $2.80
TRCPA, so for years all the 144's that have been filed never result in any selling of shares??? So maybe this time they filed because the price is gonna hit a buck soon????? LOL!!!
What you really want to see is buys at market price, not option exercising....
The "real deal" is open market purchases by officers...maybe you have never seen that.....
cashwealth...Please check your private messages...under no circumstances are you to reply to any of my posts...it upsets the Pumpers!!! Besides, if you aren't capable of addressing the subject, I don't want to read your reply anyway!! LOL!!!!
Please check if I have the PPS's at pick time correct...
Santa Claus rally....(Names and PPS at pick time)
Starshine at $11.98
Jagman at $10.90
Jagman at $6.93
SSKILL71 at $0.66
Beigledog @ $6.35
Beigledog @ $1.51
Doubloon @ $5.05
Doubloon @ $0.24
nlightn @ $489.25
nlightn @ $21.50
Sumisu @ $2.51
Sumisu @ $76.03
Waitedg @ $1.12
Waitedg @ $2.80
Santa Claus rally....(I saved my rough draft for the charts)
Sam, they should be buying!!! Haven't they read the latest DD posts???????
magicfingers, all of the DD provided by "long", self-appointed message board analysts on OTC stocks very rarely point out the MAJOR, MAJOR negatives about a company. This is your basic diluting, pump and dump POS company, IMO.... Check the shares sold the past year alone and read the last quarterly filing which is as long as Microsoft's just showing where all the shares are going. AMEP became a Business Development Company with "Investees" that never have to report their financial details......you figure it out....the investees are making all the revenue on the oil and gas sales.
This stock is a short term momo play only with spikes at PR's while the OS is going up....that has been its past history for years and it hasn't changed, IMO.
magicfingers...most of the news that I've seen said it was just the lines in the gulf that were damaged...some power losses on onshore equipment, but most of that has been repaired. I don't think it's an issue for AMEP selling gas.
CTUM...zero cash and zero revenue???? Studies in Ukraine???
$4.1 million debt???? No thanks.....
I think Greeneye owns more shares than Bitters!!!! Last Form 4 shows only 2,706,000 shares!! Think maybe he plans to make money from AMEP in other ways???? Too bad we can't see audited details from the BDC Investees and the wells (wink, wink).....
http://www.pinksheets.com/quote/print_filings.jsp?url=%2Fredirect.asp%3Ffilename%3D0001108017%252D04...
Any think the Dow will hit 11,000 before year end????
I'm glad they did that PR....shows they are still on track, IMO, even if they aren't up to investor warp speed!!! LOL!!
Too use to pump and dumpers on the pinks, I think these guys are for real and getting it done right. Maybe we'll get some exciting news before month end....
CMGI...back to my buy point, street not that impressed with earnings, but looks good going forward, hold for now.
ATEA going crazy!!! Made 75% on that one, but left money on the table!! Day traders have been going nuts with it due to low OS, one-time big customer earnings doesn't justify the pps, IMO, and insiders were dumping at $14. Want to get back in, but watch for now.
Good presentation today by NGAS, new pipeline in service, 40-60 wells going on the line, listen to presentation if you get a chance....good gas industry info and NGAS info...see PR for link...
No....I'm Warren Buffett....always looking for a "deal"...
LOLOLOLOL!!!!!
Pretty impressive management team....
How much cash do they have starting off??????
Bobsnook...that was really weird yesterday starting with the call to Sam and the crazy posts at RB. Makes me wonder if a PR is coming soon.... Will be interesting to see how this all plays out in the next few weeks...
NNAN...anyone know how big their lab is and how many lab employees??? They show one scanning electron microscope (leased?)...... Will they be dumping shares for funding????
http://www.naturalnano.com/about/index.html
I kinda like Sarah Cooper, Chief Technology Officer, .........makes me wanna buy stock...
ISON and LU deal....ISON, $2.17, gonna pop, IMO. Don't own it now, but made a bunch on it last year...
Isonics and Lucent Technologies Bell Labs to Develop Night Vision and Infrared Imaging Devices for Homeland Defense and Military Applications
Tuesday December 6, 6:00 am ET
GOLDEN, Colo. & MURRAY HILL, N.J.--(BUSINESS WIRE)--Dec. 6, 2005--Isonics (NASDAQ: ISON - News) and Lucent Technologies (NYSE: LU - News) Bell Labs announced today that they have entered into a Development Agreement whereby the two companies will endeavor to develop a next-generation infrared (IR) imaging and night vision surveillance technology based on pioneering research by Bell Labs at its micro electro-mechanical systems (MEMS) and nanotechnology fabrication facility. The development plan contemplates a proof-of-concept within 12 months, followed by steps toward commercialization.
Infrared technology, which converts infrared radiation in the non-visible spectrum, such as body heat, into a visible image, is commonly found in both commercial and military/homeland security applications including night vision goggles and cameras, rifle scopes, and threat detection devices used to identify concealed weapons or explosives.
"Isonics is proud to be working with Bell Labs to develop and commercialize this important new technology," said James E. Alexander, Chairman and CEO of Isonics Corporation. "Isonics believes that the successful commercialization of this technology has the potential to change the cost and performance dynamics of an entire industry. At the end of the day, we believe this development effort will allow Isonics to introduce products that deliver higher performance with lower power consumption at a reduced cost compared to what is currently available in the marketplace today."
"Industry research used by Isonics indicates that there is currently over a billion-dollar annual market for IR imaging and night vision cameras and systems," said Alexander. "We believe that the present market has been constrained due to the high cost of today's technologies. Isonics and Lucent have undertaken the task to extend Bell Labs' proven capability in MEMS design and fabrication to meet a large and critical national need for broader use of infrared capability on the battlefield and for homeland security. This MEMS approach has the potential for enabling new applications, even in the price-sensitive commercial and consumer sectors, due to its expected superior performance and cost effective manufacturability."
"The opportunities for growth that we expect may come to Isonics as a result of this product development initiative will usher in an important new era for our company and is consistent with our homeland security and defense mission," Alexander concluded.
Commenting on Bell Labs' agreement with Isonics, David Bishop, vice president of Bell Labs Physical Sciences and president of the New Jersey Nanotechnology Consortium, said: "Isonics is a focused, agile company with a keen eye for technology-driven product development opportunities. We look forward to collaborating with them as they leverage our MEMS-based fabrication expertise to produce exciting new products based on our powerful infrared imaging technology."
The agreement calls for cross-licensing of relevant Isonics and Bell Labs intellectual property and for Isonics to contribute to the development costs during the three-year development phase. Isonics receives exclusive rights to newly created technical information for MEMS-based IR imaging modules except for certain rights reserved by Lucent. Lucent will manufacture test structures and prototypes and has the right to manufacture commercial IR imaging modules for sale to Isonics. Isonics may incorporate these modules into IR cameras and systems it develops internally or through collaborations with others in the industry.
About Isonics Corporation
Isonics Corporation has three business divisions: (1) Homeland Security and Defense, (2) Isonics Semiconductor, and (3) Isonics Life Sciences. Isonics is a world leader in isotopically engineered materials and through its semiconductor division produces isotopically pure silicon-28 chemicals, silicon-on-insulator wafers, wafer reclaim services and test wafers, including 300mm, for the semiconductor industry. Isonics' Life Sciences division markets and sells isotopes to the health care industry for the imaging and treatment of cancer. Stable isotopes can be thought of as ultra pure materials. This high degree of purification provides enhanced properties as compared to natural materials. Our efforts in the Homeland Security segment are nascent (notwithstanding our operations at Protection Plus Security Corporation) at the present time as we proceed to develop further our IMS and neutron-based detection technologies. Additional information may be obtained at the Company's Web site at www.isonics.com.
About Bell Labs and Lucent Technologies
Lucent Technologies Bell Labs is a leading source of new communications technologies. It has played a pivotal role in inventing or perfecting key communications technologies, including transistors, digital networking and signal processing, lasers and fiber-optic communications systems, communications satellites, cellular telephony, electronic switching of calls, touch-tone dialing, and modems. Bell Labs scientists have received six Nobel Prizes in Physics, nine U.S. National Medals of Science and seven U.S. National Medals of Technology. For more information about Bell Labs, visit its Web site at http://www.bell-labs.com.
Lucent Technologies designs and delivers the systems, services and software that drive next-generation communications networks. Backed by Bell Labs research and development, Lucent uses its strengths in mobility, optical, software, data and voice networking technologies, as well as services, to create new revenue-generating opportunities for its customers, while enabling them to quickly deploy and better manage their networks. Lucent's customer base includes communications service providers, governments and enterprises worldwide. For more information on Lucent Technologies, which has headquarters in Murray Hill, N.J., USA, visit http://www.lucent.com.
Cautionary Statement
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve estimates, assumptions, known and unknown risks and uncertainties that may cause the results of this Development Agreement, each company's benefits under it, and each company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, Isonics operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond its control. Other important factors that the companies believe might cause such differences are discussed in the risk factors detailed in:
Isonics' most recent 10-KSB and reports subsequently filed with the Securities and Exchange Commission, which include Isonics' historical cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks; and
Lucent Technologies' most recent annual report on Form 10-K and other reports subsequently filed with the Securities and Exchange Commission.
The views expressed or statements made by each company are those of the company only and do not necessarily represent the views of the other company.
In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the companies' respective filings with the Securities and Exchange Commission.
Contact:
Isonics Corporation
James E. Alexander, 303-279-7900
or
Lucent Technologies Bell Labs
Peter Benedict, 908-582-7710
or
CTA Public Relations
Bevo Beaven, 303-665-4200
or
Bill Conboy, 303-665-4200
--------------------------------------------------------------------------------